Athira Pharma, Inc.

ATHA

$86M

Micro Cap

NASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaBOTHELL26 employees

Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.

Website

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 25, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

2 upcoming, 0 past

🎯PDUFANext

FDA PDUFA Date ATH-1017 (standard)

3/25/2026

For Alzheimer's disease. NDA filing. Extracted from SEC filing: 8-K

Source

🎯PDUFA

FDA PDUFA Date ATH-1017 (standard)

5/7/2026

For Alzheimer's disease. NDA filing. Extracted from SEC filing: 8-K/A

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

ATH-1017

Phase 3

Alzheimer Disease

Drug Name	Phase	Indication	Designations
ATH-1017	Phase 3	Alzheimer Disease	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

ATHA News